Kenichi Kaida

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis

Maarten J. Titulaer, Romana Höftberger, Takahiro Iizuka et al. · Annals of Neurology · 2014 · 508 citations · Full text

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven et al. · The Lancet Neurology · 2017 · 258 citations · Full text

Subcutaneous Immunoglobulin, Autoimmune Disease, Chronic Inflammatory +12

Ganglioside complexes as new target antigens in Guillain–Barré syndrome

Kenichi Kaida, Daiji Morita, Mami Kanzaki et al. · Annals of Neurology · 2004 · 170 citations

Neuro-oncology, Ganglioside Complexes, Guillain-barre Syndrome +15

Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

Sonoko Misawa, Satoshi Kuwabara, Yasunori Sato et al. · The Lancet Neurology · 2018 · 159 citations

Medicine, Neurology, Guillain-barré Syndrome +1